Alizapride: Difference between revisions

	WikiDoc Resources for Alizapride
Articles
Most recent articles on Alizapride Most cited articles on Alizapride Review articles on Alizapride Articles on Alizapride in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Alizapride Images of Alizapride Photos of Alizapride Podcasts & MP3s on Alizapride Videos on Alizapride
Evidence Based Medicine
Cochrane Collaboration on Alizapride Bandolier on Alizapride TRIP on Alizapride
Clinical Trials
Ongoing Trials on Alizapride at Clinical Trials.gov Trial results on Alizapride Clinical Trials on Alizapride at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Alizapride NICE Guidance on Alizapride NHS PRODIGY Guidance FDA on Alizapride CDC on Alizapride
Books
Books on Alizapride
News
Alizapride in the news Be alerted to news on Alizapride News trends on Alizapride
Commentary
Blogs on Alizapride
Definitions
Definitions of Alizapride
Patient Resources / Community
Patient resources on Alizapride Discussion groups on Alizapride Patient Handouts on Alizapride Directions to Hospitals Treating Alizapride Risk calculators and risk factors for Alizapride
Healthcare Provider Resources
Symptoms of Alizapride Causes & Risk Factors for Alizapride Diagnostic studies for Alizapride Treatment of Alizapride
Continuing Medical Education (CME)
CME Programs on Alizapride
International
Alizapride en Espanol Alizapride en Francais
Business
Alizapride in the Marketplace Patents on Alizapride
Experimental / Informatics
List of terms related to Alizapride

VisualWikitext

Latest revision as of 14:36, 8 April 2015

This image is provided by the National Library of Medicine.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Alizapride (Litican, Plitican, Superan, Vergentan) is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide and other benzamides.^[1]

References

↑ Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M (1988). "Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial". Cancer Chemother Pharmacol. 22 (4): 316–20. doi:10.1007/bf00254238. PMID 3048762.

Template:Propulsives

[1] Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M (1988). "Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial". Cancer Chemother Pharmacol. 22 (4): 316–20. doi:10.1007/bf00254238. PMID 3048762.

[1]

@@ Line 1: / Line 1: @@
-{{drugbox
+<div style="float: right;">
-| IUPAC_name        = ''N''-[(1-allylpyrrolidin-2-yl)methyl]-6-methoxy-<br>1''H''-benzotriazole-5-carboxamide
+[[File:Alizapride.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div>
-| image             = Alizapride.svg
+__NOTOC__
-| CAS_number        = 59338-93-1
+{{SI}}
-| ATC_prefix        = A03
+{{CMG}}
-| ATC_suffix        = FA05
+==Overview==
-| PubChem           = 43008
+'''Alizapride''' ('''Litican''', '''Plitican''', '''Superan''', '''Vergentan''') is a [[dopamine antagonist]] with [[prokinetic]] and [[antiemetic]] effects used in the treatment of [[nausea]] and [[vomiting]], including [[postoperative nausea and vomiting]]. It is  structurally related to [[metoclopramide]] and other [[benzamide]]s.<ref>{{cite journal |author=Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M |title=Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial |journal=Cancer Chemother Pharmacol |volume=22 |issue=4 |pages=316–20 |year=1988 |pmid=3048762 |doi=10.1007/bf00254238}}</ref>
-| DrugBank          =
-| C=16|H=21|N=5|O=2
-| molecular_weight  = 315.37 g/mol
-| bioavailability   =
-| protein_bound     =
-| metabolism        =
-| elimination_half-life = 3 hours
-| excretion         = [[Kidney|Renal]]
-| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
-| pregnancy_US      =  <!-- A / B            / C / D / X -->
-| pregnancy_category=
-| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
-| legal_CA          =  <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
-| legal_UK          =  <!-- GSL         / P       / POM / CD / Class A, B, C -->
-| legal_US          =  <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
-| legal_status      =
-| routes_of_administration = Oral, [[intramuscular injection|intramuscular]], [[intravenous therapy|intravenous]]
-}}
+== See also ==
+* [[Antiemetic]]
+* [[Benzamide]]
+[[File:Alizapride1.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]
+== References ==
+{{Reflist|2}}
-'''Alizapride''' is a [[dopamine antagonist]] with [[prokinetic]] and [[antiemetic]] effects used in the treatment of [[nausea]] and [[vomiting]], including [[postoperative nausea and vomiting]]. It is  structurally related to [[metoclopramide]].<ref>{{cite journal |author=Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M |title=Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial |journal=Cancer Chemother Pharmacol |volume=22 |issue=4 |pages=316–20 |year=1988 |pmid=3048762 |doi=}}</ref>
+{{Propulsives}}
-Alizapride is marketed under various trade names including '''Plitican''', '''Superan''' and '''Vergentan'''.<ref>{{fr icon}} {{cite web | url = http://www.biam2.org/www/Sub4814.html | title = Alizapride Chlorhydrate | date = [[June 2]] [[1997]] | accessdate = 2007-08-14 | publisher = BIAM}}</ref>
-==References==
-{{Reflist}}
-{{Drugs for functional gastrointestinal disorders}}
-{{WikiDoc Help Menu}}
-[[Category:Pharmacology]]
 [[Category:Antiemetics]]
 [[Category:Dopamine antagonists]]
 [[Category:Motility stimulants]]
-[[Category:Drugs]]
+[[Category:Phenol ethers]]
+[[Category:Pyrrolidines]]
+[[Category:Drug]]

Alizapride: Difference between revisions

Latest revision as of 14:36, 8 April 2015

Overview

See also

References

Navigation menu